Moderna
A page on organisations in our medical research coverage, part of our health reporting, alongside the 4 reports filed on it so far.
Intismeran-Keytruda combo cuts melanoma recurrence risk by 42%
A Phase 3 trial shows Moderna's intismeran vaccine combined with Merck's Keytruda reduces the risk of recurrence or death in high-risk melanoma...
mRNA cancer vaccine trial succeeds
A personalized mRNA vaccine for melanoma from Moderna and Merck has shown clinical success.
FDA clears three updated COVID-19 vaccines
The FDA approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax. Moderna also raised $2.6 billion for its cancer drug business.
Moderna-Merck Cancer Vaccine Shows Promise in Phase 3 Melanoma Trial
Moderna and Merck's individualized cancer vaccine shows promise in Phase 3 trial for melanoma.